Parkinson's disease (PD) is a neurodegenerative disease associated with progressive loss of motor function and cognitive decline occurring in 1% of the USA population. There is no cure for PD, and current treatment regimens are directed towards treating symptoms and not treating the underlying cause of the disease. Chronic neuroinflammation is associated with loss of neuronal cells, leading to motor and cognitive decline. Current clinical trials on drugs and nutraceuticals, such as coenzyme Q10 and niacin, are being carried out to delay progression and reduce damage by inflammatory molecules, such as reactive oxygen species and cytokines, in PD patients. In this review, we present available clinical trials and the role of niacin in reducing neuroinflammation in PD.

Original languageEnglish (US)
Pages (from-to)47-56
Number of pages10
JournalClinical and Experimental Neuroimmunology
Issue number1
StatePublished - Feb 1 2020


  • GPR109A
  • Parkinson's disease
  • microglia
  • neuroinflammation
  • niacin

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Immunology
  • Immunology and Microbiology (miscellaneous)
  • Clinical Neurology


Dive into the research topics of 'Niacin for Parkinson's disease'. Together they form a unique fingerprint.

Cite this